Insider trade

Officer sold ~$2.88M of LLY shares in the open market

Traded Jun 10, 2026 · Filed Jun 11, 2026

~$2.88M
Reported value · 2,500 sh @ $1,150.77: 30K
Holds after · shares reported: +1.2%
stock since the trade · S&P 500 +5.3%, $1,136.37 → $1,149.85 on Oct 1

Why it stands out

Eli Lilly's &Pres, LLY USA&Global Capab sold $2.88M of Eli Lilly shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 10, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 11, 2026

Officer$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,876,925

Shares × reported transaction price

Timing vs results

41 days after results of Apr 30, 2026, 56 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $1,136.37 on Jun 10, 2026, within 2% of its 52-week high, after a 30% rise over the previous 30 trading days

52-week range $625.65 (Aug 8, 2025) to $1,149.15 (Jun 8, 2026), 98% of the way up, from 251 adjusted closes. 30 trading days earlier: $874.00 on Apr 28, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Ebglyss on Jun 9, 2026, 1 day before this trade.

New use approved (efficacy supplement). Active ingredient: Lebrikizumab-Lbkz. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-2.7%	+0.4%	-3.1%
30 days	+4.3%	+1.0%	+3.3%
90 days	-0.9%	+2.2%	-3.0%

Past results only. Not a forecast.

Source receipt

Record ID: 0001826001-26-000006
Filed / recorded: Jun 11, 2026, 8:23 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: ELI LILLY & Co
Issuer CIK: 59478
Ticker: LLY
Reporting person: Ilya Yuffa
Relationship: Officer
Officer title: EVP&Pres, LLY USA&Global Capab
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jun 10, 2026
Transaction code: S
Shares / units: 2,500
Price per share: $1,150.77
Acquired / disposed: Disposed (D)
Shares owned after: 29,804.111
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2026.

Around the same time

3mo ago

Congress trade

$50,001 - $100,000Reported range · official band, not an exact amount

6 different filers disclosed LLY within 90 days. Disclosed 22 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

4mo ago

4.39Shares · @ $1,129.35

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

4mo ago

14.09Shares · @ $1,129.35

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record